Kiniksa Pharmaceuticals Sees FY2026 Sales $900.000M-$920.000M vs $902.168M Est
Benzinga Newsdesk 8 months ago
NewsGuidance
Kiniksa Pharmaceuticals (NASDAQ:KNSA) sees FY2026 sales of $900.000 million-$920.000 million vs $902.168 million analyst estimate.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) sees FY2026 sales of $900.000 million-$920.000 million vs $902.168 million analyst estimate.